Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in active recurrent or chronic TRAPS
2010-020061-24Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in TNF receptor-associated periodic syndrome (TRAPS), sponsored by Novartis. Primary endpoint: Complete or almost complete response at Day 15. Started May 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
TNF receptor-associated periodic syndrome (TRAPS)
Beyond the preview
Go deeper on 2010-020061-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020061-24.